Interest of modelling in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 30, Issue 4 SUPPL.73, 2012, Pages

  Beresniak, A ^a,b   Dupont, D M ^c   Becker, J C ^d   Merkesdal, S ^e  

^a DATA MINING INTERNATIONAL   (Switzerland)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Data Mining America   (Canada)

^d Becker Clinical Research Consulting   (United States)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Modelling; QALY; Rheumatoid arthritis

Indexed keywords

ARTICLE; ARTIFICIAL NEURAL NETWORK; DECISION TREE; MODEL; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLUSTER ANALYSIS; COST-BENEFIT ANALYSIS; DECISION TREES; ECONOMICS, PHARMACEUTICAL; HUMANS; MARKOV CHAINS; MODELS, ECONOMETRIC; MODELS, ECONOMIC; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS;

EID: 84870266436     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. SUTER LG, FRAENKEL L, BRAITHWAITE RS: Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management. Arch Intern Med 2011;171:657-67.
2. LUNT M, SYMMONS DP, SILMAN AJ: An evaluation of the decision tree format of the american college of rheumatology 1987 classification criteria for rheumatoid arthritis: Performance over five years in a primary care-based prospective study. Arthritis Rheum 2005;52:2277-83.
3. HALLINEN TA, SOINI EJ, EKLUND K, PUOLAKKA K: Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology (Oxford) 2010;49:767-77.
4. SCHIPPER LG, KIEVIT W, DEN BROEDER AA et al.: Treatment strategies aiming at remission in early rheumatoid arthritis patients: Starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford) 2011;50:1320-30.
5. RUSSELL A, BERESNIAK A, BESSETTE L et al.: Cost-effectiveness modeling of abatacept versus other biologic agents in dmards and anti-tnf inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin Rheumatol 2009;28:403-12
6. SARAUX A, GOSSEC L, GOUPILLE P et al.: Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in france. Rheumatology (Oxford) 2010;49:733-40.
7. CIMMINO MA, LEARDINI G, SALAFFI F et al.: Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in italy: A modelling approach. Clin Exp Rheumatol 2011;29:633-41
8. BERESNIAK A, ARIZA-ARIZA R, GARCIA-LLORENTE JF, RAMIREZ-ARELLANO A, DUPONT D: Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain. Int J Inflam 2011;2011:727634.
9. PUOLAKKA K, BLÅFIELD H, KAUPPI M et al.: Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in finland. Open Rheumatol J 2012;6:38-43.
10. LAKOTA K, THALLINGER GG, SODIN-SEMRL S et al.: International cohort study of 73 antiku-positive patients: Association of p70/p80 anti-ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. Arthritis Res Ther 2012;14:R2.
11. MICHAUD K, MESSER J, CHOI HK, WOLFE F: Direct medical costs and their predictors in patients with rheumatoid arthritis: A threeyear study of 7, 527 patients. Arthritis Rheum 2003;48:2750-62.
12. MITCHELL JM, BURKHAUSER RV, PINCUS T: The importance of age, education, and comorbidity in the substantial earnings losses of individuals with symmetric polyarthritis. Arthritis Rheum 1988;31:348-57.
13. NGUYEN CM, BOUNTHAVONG M, MENDES MA et al.: Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: An application of bayesian methods for evidence synthesis in a markov model. Pharmacoeconomics 2012;30:575-93.
14. STAHL EA, WEGMANN D, TRYNKA G et al.: Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet 2012;44:483-9.
15. MCTAGGART-COWAN HM, BRAZIER JE, TSUCHIYA A: Clustering rash results: A novel method for developing rheumatoid arthritis states for use in valuation studies. Value Health 2010;13:787-95.
16. SORDO M: Introduction to neural networks in health care. Open Clinical 2002; Harvard: 1-17.
17. NOLTING J: Developing a neural network model for health care. AMIA Annu Symp Proc 2006:1049.
18. ZHA QL, HE YT, YAN XP et al.: Predictive role of diagnostic information in treatment efficacy of rheumatoid arthritis based on neural network model analysis. Zhong Xi Yi Jie He Xue Bao 2007;5:32-8.
19. ZHOU Z, MAO Z, DENG Z: Neural network approach to medical grading of rheumatoid arthritis. Sheng Wu Yi Xue Gong Cheng Xue ZaZhi 1999;16:479-82.
20. MC GREGOR M, CARO JJ: Qalys: Are they helpful to decision makers? Pharmacoeconomics 2006;24:947-52.
21. BERESNIAK A, RUSSELL AS, HARAOUI B, BESSETTE L, BOMBARDIER C, DURU G: Advantages and limitations of utility assessment methods in rheumatoid arthritis. J Rheumatol 2007;34:2193-200.
22. RAMSEY S: Is there an international backlash against cost-utility analysis? ISPOR Connections 2010;16:3.
23. DURU G, AURAY JP, BERESNIAK A, LAMURE M, PAINE A, NICOLOYANNIS N: Limitations of the methods used for calculating qualityadjusted life-year values. Pharmacoeconomics 2002;20:463-73.
24. SOINI EJ, HALLINEN TA, PUOLAKKA K, VIHERVAARA V, KAUPPI MJ: Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderateto-severe rheumatoid arthritis. J Med Econ 2012;15:340-51.
25. KOBELT G, LEKANDER I, LANG A, RAFFEINER B, BOTSIOS C, GEBOREK P: Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care 2011;27:193-200.
26. TOSH JC, WAILOO AJ, SCOTT DL, DEIGHTON CM: Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis. J Rheumatol 2011;38:1593-600.